CA2452358C - Biodegradable polymer systems - Google Patents
Biodegradable polymer systems Download PDFInfo
- Publication number
- CA2452358C CA2452358C CA2452358A CA2452358A CA2452358C CA 2452358 C CA2452358 C CA 2452358C CA 2452358 A CA2452358 A CA 2452358A CA 2452358 A CA2452358 A CA 2452358A CA 2452358 C CA2452358 C CA 2452358C
- Authority
- CA
- Canada
- Prior art keywords
- anhydride
- acid
- additive
- polymer blend
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L17/00—Materials for surgical sutures or for ligaturing blood vessels ; Materials for prostheses or catheters
- A61L17/06—At least partially resorbable materials
- A61L17/10—At least partially resorbable materials containing macromolecular materials
- A61L17/12—Homopolymers or copolymers of glycolic acid or lactic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
- A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/0401—Suture anchors, buttons or pledgets, i.e. means for attaching sutures to bone, cartilage or soft tissue; Instruments for applying or removing suture anchors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/04—Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
- A61B17/06—Needles ; Sutures; Needle-suture combinations; Holders or packages for needles or suture materials
- A61B17/06166—Sutures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/72—Intramedullary pins, nails or other devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/80—Cortical plates, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/80—Cortical plates, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates
- A61B17/8061—Cortical plates, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates specially adapted for particular bones
- A61B17/8071—Cortical plates, i.e. bone plates; Instruments for holding or positioning cortical plates, or for compressing bones attached to cortical plates specially adapted for particular bones for the jaw
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/86—Pins or screws or threaded wires; nuts therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/56—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor
- A61B17/58—Surgical instruments or methods for treatment of bones or joints; Devices specially adapted therefor for osteosynthesis, e.g. bone plates, screws, setting implements or the like
- A61B17/68—Internal fixation devices, including fasteners and spinal fixators, even if a part thereof projects from the skin
- A61B17/84—Fasteners therefor or fasteners being internal fixation devices
- A61B17/86—Pins or screws or threaded wires; nuts therefor
- A61B17/866—Material or manufacture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B2017/00004—(bio)absorbable, (bio)resorbable, resorptive
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2250/00—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
- A61F2250/0014—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis
- A61F2250/003—Special features of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof having different values of a given property or geometrical feature, e.g. mechanical property or material property, at different locations within the same prosthesis differing in adsorbability or resorbability, i.e. in adsorption or resorption time
Abstract
The rate of degradation of polymers and polymer blends containing (poly) lactic acid can be increased and controlled by the inclusion of up to 10%
(typically less than 1%) by weight of specific additives such as lauric acid or a derivative thereof such as the anhydride.
(typically less than 1%) by weight of specific additives such as lauric acid or a derivative thereof such as the anhydride.
Description
Biodegradable Polymer Systems This invention relates to biodegradable polymeric materials, particularly to bioresorbable materials and to artifacts made therefrom.
Poly (lactic acid), also commonly known as PLA has been widely used, either as the D-isomer or the mixed DL-form, for the manufacture of implant materials where bioresorbabilty is a required property. Although PLA is biodegradable it will normally take from 3 to 5 years to be fully resorbed. A further disadvantage is that although it takes 3 to 5 years to fully degrade the mechanical strength of implants made from poly (L-lactic acid)(PLLA) will be lost within a fifth of that time The in vivo degradation of PLA takes place predominately via an autocatalysed hydrolytic scission of the ester groups in the polymer chain according to the reaction:
-COO- + H20 COOH Ow--COOH + HO-Attempts to increase the carboxylic acid functionality of the polymeric material and, hence, increase the rate of degradation of PLA have been reported in the literature ("Modification of the rates of chain cleavage of poly (---caprolactone) and related polyesters in the solid state',Journal of Controlled Release, 4, (1987) pp283-292.) in which samples of PLA have been contacted with carboxyl group-containing materials such as oleic acid. No effect on the rate of degradation was reported. The effect of lactic acid monomer in PLA
has also been investigated and 'reported ("Effects of residual monomer on the degradation of DL-lactide polymer" Hyon, Jamshidi & Ikada, Polymer International, 46 (1998), pp196-202). However, it was found that the added monomer rapidly leached out of the polymer. Polymer blends containing 15 weight percent lactic acid exhibited a total weight loss of about 15% within the first week of a 10 week study and very little further loss in the remaining weeks.
Poly (lactic acid), also commonly known as PLA has been widely used, either as the D-isomer or the mixed DL-form, for the manufacture of implant materials where bioresorbabilty is a required property. Although PLA is biodegradable it will normally take from 3 to 5 years to be fully resorbed. A further disadvantage is that although it takes 3 to 5 years to fully degrade the mechanical strength of implants made from poly (L-lactic acid)(PLLA) will be lost within a fifth of that time The in vivo degradation of PLA takes place predominately via an autocatalysed hydrolytic scission of the ester groups in the polymer chain according to the reaction:
-COO- + H20 COOH Ow--COOH + HO-Attempts to increase the carboxylic acid functionality of the polymeric material and, hence, increase the rate of degradation of PLA have been reported in the literature ("Modification of the rates of chain cleavage of poly (---caprolactone) and related polyesters in the solid state',Journal of Controlled Release, 4, (1987) pp283-292.) in which samples of PLA have been contacted with carboxyl group-containing materials such as oleic acid. No effect on the rate of degradation was reported. The effect of lactic acid monomer in PLA
has also been investigated and 'reported ("Effects of residual monomer on the degradation of DL-lactide polymer" Hyon, Jamshidi & Ikada, Polymer International, 46 (1998), pp196-202). However, it was found that the added monomer rapidly leached out of the polymer. Polymer blends containing 15 weight percent lactic acid exhibited a total weight loss of about 15% within the first week of a 10 week study and very little further loss in the remaining weeks.
In US Patent Specification No. 5 527 337 there is disclosed a biodegradeable stent formed from lactide polymers wherein, inter alia, an excipient such as ctric acid or fumaric acid can be incorporated during the polymer processing. Other additives which which can be used to accelerate stent degradation which are not acids themselves are also disclosed including the tertiary butyl ester of lauric acid and the ditertiary butyl ester of fumaric acid.
US Patent Specification No. 6 248 430 describes a laminate, for use in the manufacture of molded products for agricultural or civil engineering purposes. The laminate consists of a base layer comprising a lactic acid-based polymer having a degradation accelerator incorporated therein and a barrier layer which comprises a lactic acid based polymer having a lactide content of not more than 0.1 % by weight, for the purpose of preventing the accelerator from leaking from the base polymer. The lactic acid-based polymer comprises a polyester made of polylactic acid component, lactic acid component dicarboxylic acid component, diol component and/or polyether component or a mixture thereof. Examples of materials useful as an accelerator include organic acids such as lactic, glyceric, tartaric, citric, lauric, stearic, oleic, succinic, adipic sebacic, benzoic and phthalic acids. The disclosure shows that the accelerators are incorporated during the polymer forming process.
Although it is known in the prior art to attempt to increase the carboxyl functionality by using acid based accelerators it has been a problem to retain such accelerators within the polymer mass for a sufficient period of time to allow control of the rate of degradation.
The prior attempts to control degradation require either the use of physical barrier layers to retain the accelerator or the use of complex polymer systems.
We have now found that it is possible to control the rate of degradation of lactic acid polymers by homogeously blending certain additives which are both fully miscible with PLA and will not leach out. The blending process is simple and results in stable polymer blends which can be readily thermoformed, such as by injection molding to form implantable medical devices which will both maintain their physical strength yet biodegrade in a predictable manner.
Thus in accordance with the present invention there is provided an implantable, biodegradable medical device formed from a homogeneous polymer blend comprising a poly lactic acid in admixture,in an amount of not more than 10% by weight of the polymer blend, with an additive which is an acid or a derivative thereof selected from the group consisting of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4-hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2-butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3-methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans-beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen-1-yl succinic anhydride and phthalic anhydride.
The additive concentration is chosen such that it must be fully miscible with the polymer blend and should not leach out of the polymer.
US Patent Specification No. 6 248 430 describes a laminate, for use in the manufacture of molded products for agricultural or civil engineering purposes. The laminate consists of a base layer comprising a lactic acid-based polymer having a degradation accelerator incorporated therein and a barrier layer which comprises a lactic acid based polymer having a lactide content of not more than 0.1 % by weight, for the purpose of preventing the accelerator from leaking from the base polymer. The lactic acid-based polymer comprises a polyester made of polylactic acid component, lactic acid component dicarboxylic acid component, diol component and/or polyether component or a mixture thereof. Examples of materials useful as an accelerator include organic acids such as lactic, glyceric, tartaric, citric, lauric, stearic, oleic, succinic, adipic sebacic, benzoic and phthalic acids. The disclosure shows that the accelerators are incorporated during the polymer forming process.
Although it is known in the prior art to attempt to increase the carboxyl functionality by using acid based accelerators it has been a problem to retain such accelerators within the polymer mass for a sufficient period of time to allow control of the rate of degradation.
The prior attempts to control degradation require either the use of physical barrier layers to retain the accelerator or the use of complex polymer systems.
We have now found that it is possible to control the rate of degradation of lactic acid polymers by homogeously blending certain additives which are both fully miscible with PLA and will not leach out. The blending process is simple and results in stable polymer blends which can be readily thermoformed, such as by injection molding to form implantable medical devices which will both maintain their physical strength yet biodegrade in a predictable manner.
Thus in accordance with the present invention there is provided an implantable, biodegradable medical device formed from a homogeneous polymer blend comprising a poly lactic acid in admixture,in an amount of not more than 10% by weight of the polymer blend, with an additive which is an acid or a derivative thereof selected from the group consisting of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4-hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2-butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3-methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans-beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen-1-yl succinic anhydride and phthalic anhydride.
The additive concentration is chosen such that it must be fully miscible with the polymer blend and should not leach out of the polymer.
As used herein the term "fully miscible" means that when an 0.5mm thick sheet of the polymer blend is visually inspected the sheet is either uniformly transparent or, if the sheet is opaque, the opacity is uniform.
As used herein the term "not leach out of the polymer" is defined such that when a thin (thickness <1 mm) sample is immersed in an excess of PBS (Phosphate buffer solution), at least half of the added additive remains in the sample after 1 week.
Aptly the polymer blend will contain not more than 5%, more preferably not more than 2%, by weight of the additive and typically the blend will contain not more than 1% by weight of the additive.
Preferred blends will contain not more than 2%, more preferably not more than 1%, by weight of the blend of lauric acid or a derivative thereof.
The amount of the additive chosen will also depend upon the rate of degradation desired. In vivo degradation occurs firstly by hydrolytic scission of the ester groups resulting in the formation of units of increasingly smaller molecular weight until only substantially lactic acid monomer remains. Thereafter, the lactic acid is metabolized and absorbed into the body. It is only in the last stages of degradation that mass loss occurs.
The mechanical properties of the implant are retained in the early stages of degradation, even though the molecular weight may decrease markedly. Eventually a critical molecular weight is reached and the implant will cease to have any useful mechanical strength yet will not have degraded sufficiently for resorption to occur.
We have found that a preferred additive for use in the invention is lauric acid. This may be employed as the acid per se or, if desired, as a derivative, for example as the anhydride.
As used herein the term "not leach out of the polymer" is defined such that when a thin (thickness <1 mm) sample is immersed in an excess of PBS (Phosphate buffer solution), at least half of the added additive remains in the sample after 1 week.
Aptly the polymer blend will contain not more than 5%, more preferably not more than 2%, by weight of the additive and typically the blend will contain not more than 1% by weight of the additive.
Preferred blends will contain not more than 2%, more preferably not more than 1%, by weight of the blend of lauric acid or a derivative thereof.
The amount of the additive chosen will also depend upon the rate of degradation desired. In vivo degradation occurs firstly by hydrolytic scission of the ester groups resulting in the formation of units of increasingly smaller molecular weight until only substantially lactic acid monomer remains. Thereafter, the lactic acid is metabolized and absorbed into the body. It is only in the last stages of degradation that mass loss occurs.
The mechanical properties of the implant are retained in the early stages of degradation, even though the molecular weight may decrease markedly. Eventually a critical molecular weight is reached and the implant will cease to have any useful mechanical strength yet will not have degraded sufficiently for resorption to occur.
We have found that a preferred additive for use in the invention is lauric acid. This may be employed as the acid per se or, if desired, as a derivative, for example as the anhydride.
5 By the use of the blends for the present invention not only may the total rate of degradation and resorption be controlled but it is possible to control the rate of degradation in order to optimize the mechanical properties. In many, surgical procedures, where the implant is required to provide temporary support until the condition has been treated by the body's own natural repair or rebuilding activity. When the support provided by the implant is no longer required it is often desirable that the strength of the implant be markedly reduced.
Thus in accordance with a further embodiment of the present invention there is provided an implantable, biodegradable medical device having predetermined strength retention comprising a homogeneous blend of a polylactic acid in admixture with an additive as hereinabove defined, in an amount, calculated as weight percent, based on the weight of the total polymer blend represented by the following equation:
..lT 12 Mn 0 - tkl %additive = MnA * 100 ~ Mns -- 1 tk2 -Mn 0 where :-Mno = polymer initial molecular weight Mns = Mn at which the polymer looses strength MnA = molecular weight of the acid t = Duration (weeks) that strength retention is required k, = constant 1 k2 = constant 2 The constants k, and k2 are the slope and intercept of a graph of the degradation rate of a blend against the square root of the total number of COOH groups in the blend. The degradation rate of a blend is the slope of a graph of Ln(Mn) against degradation time in weeks.
The degradation rates of the additives employed as 2% by weight component in a polylactic acid blend in the present invention are shown in the following table:
Additive Degradation rate Hexanoic acid -0.0565 Octanoic acid -0.0448 Decanoic acid -0.0472 Lauric acid -0.0326 Myristic acid -0.0281 Crotonic acid -0.0489 4-Pentenoic acid -0.0567 2-Hexenoic acid -0.0713 Undecylenic acid -0.07 Petroselenic acid -0.0542 Oleic acid -0.0442 Erucic acid -0.0315 2,4-Hexadienoic acid -0.0618 Linoleic acid -0.0488 Linolenic acid -0.0589 Benzoic acid -0.0798 Hydrocinnamic acid -0.0737 4-Isopropylbenzoic acid -0.0728 Ibuprofen -0.051 Ricinoleic acid -0.061 Adipic acid -0.0373 Suberic acid -0.0311 Phthalic acid -0.0855 2-Bromolauric acid -0.0769 2,4-Hydroxydodecanoic acid -0.0318 Monobutyrin -0.0347 2-Hexyldecanoic acid -0.0339 2-Butyloctanoic acid -0.0467 2-Ethylhexanoic acid -0.0473 2-Methylvaleric acid -0.0411 3-Methylvaleric acid -0.0587 4-Methylvaleric acid -0.0553 2-Ethylbutyric acid -0.053 Trans-beta-hydromuconic acid -0.039 Isovaleric anhydride -0.0628 Hexanoic anhydride -0.0919 Decanoic anhydride -0.0807 Lauric anhydride -0.0698 Myristic anhydride -0.0626 4-Pentenoic anhydride -0.0888 Oleic anhydride -0.0504 Linoleic anhydride -0.0696 Benzoic anhydride -0.0817 Poly(azefaic anhydride) -0.0784 2-Octen-1-yl succinic anhydride -0.1012 Phthalic anhydride -0.0841 A further embodiment of the present invention provides the provision of an additive which not only will control the rate of degradation but will delay the onset of the degradation process. This delay may be achieved, aptly by the use of additives which are convertible to the acidic form of the additive. Suitable derivatives are acid anhydrides which will, in an in vivo environment hydrolyse to the corresponding acid. Preferred anhydrides include lauric anhydride and benzoic anhydride, in amounts of, aptly, not more than 5%, more aptly, not more than 2% and, typically, not more than 1 /o by weight of the polymer blend.
Thus specifically the present invention provides an implantable, biodegradable medical device having predetermined strength retention comprising a homogeneous blend of a polylactic acid in admixture with lauric anhydride or benzoic anhydride in an amount, calculated as weight percent, based on the weight of the total polymer blend, represented by the following equation:
LYZ Mn 0 - tkl %additive = Ma * 100 * (Mns - 1 tk2 Mn 0 where Mno, MõS, MõA, k, and k2 are as defined herein and t is the duration (weeks) that strength retention is required once onset of degradation has comenced The polymeric component of the polymer blends useful for the invention essentially comprise a poly lactic acid. The poly lactic acid may be present as a homopolymer or as a co-polymer, for example a co-polymer of lactic acid and glycolic acid (known as PLA/PGA co-polymer). The polymer blend may also contain other polymeric components blended therewith. Thus the blend may, in addition to the additive, consist of a blend of polylactic acid, PLA/PGA co-polymer. Other examples of suitable blend include blends of PLA or PLA/PGA co-polymer either alone or in admixture with each other, together with hydroxy apatite.
The polymer blends used for the present invention may be produced by known processes such as solution blending wherein the additive is blended directly into a solution of a polymeric component comprising PLA in, for example, chloroform. The solution blend is then dried.
Thus in accordance with a further embodiment of the present invention there is provided an implantable, biodegradable medical device having predetermined strength retention comprising a homogeneous blend of a polylactic acid in admixture with an additive as hereinabove defined, in an amount, calculated as weight percent, based on the weight of the total polymer blend represented by the following equation:
..lT 12 Mn 0 - tkl %additive = MnA * 100 ~ Mns -- 1 tk2 -Mn 0 where :-Mno = polymer initial molecular weight Mns = Mn at which the polymer looses strength MnA = molecular weight of the acid t = Duration (weeks) that strength retention is required k, = constant 1 k2 = constant 2 The constants k, and k2 are the slope and intercept of a graph of the degradation rate of a blend against the square root of the total number of COOH groups in the blend. The degradation rate of a blend is the slope of a graph of Ln(Mn) against degradation time in weeks.
The degradation rates of the additives employed as 2% by weight component in a polylactic acid blend in the present invention are shown in the following table:
Additive Degradation rate Hexanoic acid -0.0565 Octanoic acid -0.0448 Decanoic acid -0.0472 Lauric acid -0.0326 Myristic acid -0.0281 Crotonic acid -0.0489 4-Pentenoic acid -0.0567 2-Hexenoic acid -0.0713 Undecylenic acid -0.07 Petroselenic acid -0.0542 Oleic acid -0.0442 Erucic acid -0.0315 2,4-Hexadienoic acid -0.0618 Linoleic acid -0.0488 Linolenic acid -0.0589 Benzoic acid -0.0798 Hydrocinnamic acid -0.0737 4-Isopropylbenzoic acid -0.0728 Ibuprofen -0.051 Ricinoleic acid -0.061 Adipic acid -0.0373 Suberic acid -0.0311 Phthalic acid -0.0855 2-Bromolauric acid -0.0769 2,4-Hydroxydodecanoic acid -0.0318 Monobutyrin -0.0347 2-Hexyldecanoic acid -0.0339 2-Butyloctanoic acid -0.0467 2-Ethylhexanoic acid -0.0473 2-Methylvaleric acid -0.0411 3-Methylvaleric acid -0.0587 4-Methylvaleric acid -0.0553 2-Ethylbutyric acid -0.053 Trans-beta-hydromuconic acid -0.039 Isovaleric anhydride -0.0628 Hexanoic anhydride -0.0919 Decanoic anhydride -0.0807 Lauric anhydride -0.0698 Myristic anhydride -0.0626 4-Pentenoic anhydride -0.0888 Oleic anhydride -0.0504 Linoleic anhydride -0.0696 Benzoic anhydride -0.0817 Poly(azefaic anhydride) -0.0784 2-Octen-1-yl succinic anhydride -0.1012 Phthalic anhydride -0.0841 A further embodiment of the present invention provides the provision of an additive which not only will control the rate of degradation but will delay the onset of the degradation process. This delay may be achieved, aptly by the use of additives which are convertible to the acidic form of the additive. Suitable derivatives are acid anhydrides which will, in an in vivo environment hydrolyse to the corresponding acid. Preferred anhydrides include lauric anhydride and benzoic anhydride, in amounts of, aptly, not more than 5%, more aptly, not more than 2% and, typically, not more than 1 /o by weight of the polymer blend.
Thus specifically the present invention provides an implantable, biodegradable medical device having predetermined strength retention comprising a homogeneous blend of a polylactic acid in admixture with lauric anhydride or benzoic anhydride in an amount, calculated as weight percent, based on the weight of the total polymer blend, represented by the following equation:
LYZ Mn 0 - tkl %additive = Ma * 100 * (Mns - 1 tk2 Mn 0 where Mno, MõS, MõA, k, and k2 are as defined herein and t is the duration (weeks) that strength retention is required once onset of degradation has comenced The polymeric component of the polymer blends useful for the invention essentially comprise a poly lactic acid. The poly lactic acid may be present as a homopolymer or as a co-polymer, for example a co-polymer of lactic acid and glycolic acid (known as PLA/PGA co-polymer). The polymer blend may also contain other polymeric components blended therewith. Thus the blend may, in addition to the additive, consist of a blend of polylactic acid, PLA/PGA co-polymer. Other examples of suitable blend include blends of PLA or PLA/PGA co-polymer either alone or in admixture with each other, together with hydroxy apatite.
The polymer blends used for the present invention may be produced by known processes such as solution blending wherein the additive is blended directly into a solution of a polymeric component comprising PLA in, for example, chloroform. The solution blend is then dried.
The thus formed solid blend may then be formed per se into the medical device of the invention, by known processes such as compression moulding or extrusion or into components, such as fibres which may be further processed to form devices in accordance with the present invention.
Alternatively, the blends may be further blended or ortherwise formulated with other materials to form medical devices in accordance with the invention. Thus the additive-containing blends may be utilized as the matrix component of a composite material which is then fabricated into a biodegradable medical device.
The medical devices of the invention are biodegradable and any implantable devices where temporary residence only is required.
Examples of such devices include sutures, suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods.
The polymer blends themselves are believed to be novel compositions of matter.
Accordingly, the present invention further provides a polymer blend, useful for the manufacture of biodegradable medical devices comprising polylactic acid in admixture with an additive in an amount of not more than 10% by weight of the blend of at least one of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4-hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2-butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3-methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans-beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic 5 anhydride, poly(azelaic anhydride), 2-octen-l-yi succinic anhydride or phthaiic anhydride.
Aptly the blend will comprise not more than 5% by weight of the additive and preferably no more than 2% by weight of the 10 'additive.
The present invention will be illustrated by reference to the following and accompanying drawings.
Figure 1 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 1;
Figure 2 1 is a graph showing the lauric acid remaining in the samples as determined by GC-MS;
Figure 3 is a graph showing the lactic acid content of the phosphate buffer solution in which the samples are immersed, as a measurement of resorption potential;
Figure 4 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 2;
Figure 5 is a graph showing the lactic acid content of the phosphate buffer solution in which the samples of Example 2 are immersed, as a measurement of resorption potential;
Figure 6 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 3;
Figure 7 is a graph showing the tensile strength of samples prepared in accordance with Example 3;
Figure 8 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 5;
10a Figure 9 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 6;
and Figure 10 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 7.
Example I
Blends of poly(L-lactic acid) containing lauric acid, in amounts respectively, 2% and 5% by weight of the blend, were prepared by first dry blending the solid materials and then solution blending the materials by roller mixing the solid mixture(10% by weight) with chloroform (90% by weight). After complete dissolution of the solids, the solutions were cast onto an open tray, left to dry (in a fume cupboard) at ambient temperature for 24 hours and dried for a further 24 hours under vacuum at ambient temperature. A control sample was also prepared by solution blending poly(L-lactic acid) alone with chloroform and drying the cast solution under the same conditions as the lauric acid-containing samples.
The dried cast films were then comminuted and approximately 10gm charges of the blends were compression moulded between two sheets of mould release sheets maintained 0.5mm apart. The charges were warmed for 5 minutes prior to moulding and fed into the mould at a temperature of 195 C , pressure of 100N over a period of 90 seconds to form sheets. The resultant sheets were observed to be transparent.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 10 weeks.
During the ten week test period samples were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o to determine the lauric acid in the polymer (to measure the degree of leaching of the lauric acid additive), o to determine the amount of Lactic acid in the PBS (to measure the amount of degradation products released into the PBS buffer).
The decrease in molecular weight is reported in Figure 1. The lauric acid remaining in the sample was determined by GC-MS.
Samples were weighed (-50mg) and 2ml chloroform added. These were sonicated until the polymer dissolved. 20m1 of diethyl ether was added to precipitate out the polymer, this was transferred to a 50m1 volumetric and made to the mark with diethyl ether. An aliquot of the samples was vialled for analysis by GC-MS. The results for samples at weeks 0 and 10 are shown in Figure 2.
Samples of the PBS were also analysed by HPLC to determine the amount of lactic acid (to measure resorption potential). 31 ml aliquots of the PBS were taken at each time interval and analysed under the following conditions:
Alternatively, the blends may be further blended or ortherwise formulated with other materials to form medical devices in accordance with the invention. Thus the additive-containing blends may be utilized as the matrix component of a composite material which is then fabricated into a biodegradable medical device.
The medical devices of the invention are biodegradable and any implantable devices where temporary residence only is required.
Examples of such devices include sutures, suture anchors, soft tissue anchors, interference screws, tissue engineering scaffolds, maxillo-facial plates, fracture fixation plates and rods.
The polymer blends themselves are believed to be novel compositions of matter.
Accordingly, the present invention further provides a polymer blend, useful for the manufacture of biodegradable medical devices comprising polylactic acid in admixture with an additive in an amount of not more than 10% by weight of the blend of at least one of hexanoic acid, octanoic acid, decanoic acid, lauric acid, myristic acid, crotonic acid, 4-pentenoic acid, 2-hexenoic acid, undecylenic acid, petroselenic acid, oleic acid, erucic acid, 2,4-hexadienoic acid, linoleic acid, linolenic acid, benzoic acid, hydrocinnamic acid, 4-isopropylbenzoic acid, ibuprofen, ricinoleic acid, adipic acid, suberic acid, phthalic acid, 2-bromolauric acid, 2,4-hydroxydodecanoic acid, monobutyrin, 2-hexyldecanoic acid, 2-butyloctanoic acid, 2-ethylhexanoic acid, 2-methylvaleric acid, 3-methylvaleric acid, 4-methylvaleric acid, 2-ethylbutyric acid, trans-beta-hydromuconic acid, isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic 5 anhydride, poly(azelaic anhydride), 2-octen-l-yi succinic anhydride or phthaiic anhydride.
Aptly the blend will comprise not more than 5% by weight of the additive and preferably no more than 2% by weight of the 10 'additive.
The present invention will be illustrated by reference to the following and accompanying drawings.
Figure 1 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 1;
Figure 2 1 is a graph showing the lauric acid remaining in the samples as determined by GC-MS;
Figure 3 is a graph showing the lactic acid content of the phosphate buffer solution in which the samples are immersed, as a measurement of resorption potential;
Figure 4 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 2;
Figure 5 is a graph showing the lactic acid content of the phosphate buffer solution in which the samples of Example 2 are immersed, as a measurement of resorption potential;
Figure 6 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 3;
Figure 7 is a graph showing the tensile strength of samples prepared in accordance with Example 3;
Figure 8 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 5;
10a Figure 9 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 6;
and Figure 10 is a graph showing the decrease in molecular weight of polymer blend samples prepared in accordance with Example 7.
Example I
Blends of poly(L-lactic acid) containing lauric acid, in amounts respectively, 2% and 5% by weight of the blend, were prepared by first dry blending the solid materials and then solution blending the materials by roller mixing the solid mixture(10% by weight) with chloroform (90% by weight). After complete dissolution of the solids, the solutions were cast onto an open tray, left to dry (in a fume cupboard) at ambient temperature for 24 hours and dried for a further 24 hours under vacuum at ambient temperature. A control sample was also prepared by solution blending poly(L-lactic acid) alone with chloroform and drying the cast solution under the same conditions as the lauric acid-containing samples.
The dried cast films were then comminuted and approximately 10gm charges of the blends were compression moulded between two sheets of mould release sheets maintained 0.5mm apart. The charges were warmed for 5 minutes prior to moulding and fed into the mould at a temperature of 195 C , pressure of 100N over a period of 90 seconds to form sheets. The resultant sheets were observed to be transparent.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 10 weeks.
During the ten week test period samples were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o to determine the lauric acid in the polymer (to measure the degree of leaching of the lauric acid additive), o to determine the amount of Lactic acid in the PBS (to measure the amount of degradation products released into the PBS buffer).
The decrease in molecular weight is reported in Figure 1. The lauric acid remaining in the sample was determined by GC-MS.
Samples were weighed (-50mg) and 2ml chloroform added. These were sonicated until the polymer dissolved. 20m1 of diethyl ether was added to precipitate out the polymer, this was transferred to a 50m1 volumetric and made to the mark with diethyl ether. An aliquot of the samples was vialled for analysis by GC-MS. The results for samples at weeks 0 and 10 are shown in Figure 2.
Samples of the PBS were also analysed by HPLC to determine the amount of lactic acid (to measure resorption potential). 31 ml aliquots of the PBS were taken at each time interval and analysed under the following conditions:
Mobile Phase: 0.005N H2SO4 in water Column: Rezex 8 8% H. Organic Acids - 300 x 7.80 mm Flow Rate: 0.6 ml/min Injection Volume: 100 1 Column Temperature:
Wavelength: 210 nm Runtime 20 min The lactic acid content of the PBS is shown in Figure 3.
Example 2 Blends of poly(DL-lactic acid) containing lauric acid, in amounts respectively, 2% and 4% by weight of the blend, were prepared using the method described for Example 1.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o Lactic acid (to measure the amount of degradation products released into the PBS buffer).
The decrease in molecular weight is reported in Figure 4, the lactic acid released into the PBS buffer in Figure 5.
Wavelength: 210 nm Runtime 20 min The lactic acid content of the PBS is shown in Figure 3.
Example 2 Blends of poly(DL-lactic acid) containing lauric acid, in amounts respectively, 2% and 4% by weight of the blend, were prepared using the method described for Example 1.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o Lactic acid (to measure the amount of degradation products released into the PBS buffer).
The decrease in molecular weight is reported in Figure 4, the lactic acid released into the PBS buffer in Figure 5.
Example 3 A blend of poly(L-lactic acid) containing 5% lauric acid was prepared by first dry blending the solid materials and then solution blending the materials by roller mixing the solid mixture (10% by weight) with chloroform (90% by weight). After complete dissolution of the solids, the solutions were cast onto an open tray, left to dry (in a fume cupboard) at ambient temperature for 24 hours and dried for a further 24 hours under vacuum at ambient temperature. A control sample was also prepared by solution blending poly(L-lactic acid) alone with chloroform and drying the cast solution under the same conditions as the lauric acid-containing samples.
The dried cast films were then comminuted and extruded at 180 C to produce rods with a diameter of approx 2mm. The resultant rods were observed to be slightly opaque, but uniform in colour.
The rods were then subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples of the billets were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o to determine the tensile strength of the rods.
The decrease in molecular weight is reported in Figure 6. The tensile strength of the rods was measured using a gauge length of 40mm and a test speed of 10mm/min, the results are reported in Figure 7.
The dried cast films were then comminuted and extruded at 180 C to produce rods with a diameter of approx 2mm. The resultant rods were observed to be slightly opaque, but uniform in colour.
The rods were then subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples of the billets were analysed:
o to determine molecular weight of the polymer blend(to measure the degree of degradation), o to determine the tensile strength of the rods.
The decrease in molecular weight is reported in Figure 6. The tensile strength of the rods was measured using a gauge length of 40mm and a test speed of 10mm/min, the results are reported in Figure 7.
Example 4 A blend of poly(L-lactic acid) containing 1% lauric acid was prepared by first dry blending the solid materials and then extruding the mixture at 195 C. The subsequent polymer blend was then analysed to determine the lauric acid content, which was measured at 0.9%. The resultant rod material was observed to be transparent.
Example 5 Blends of poly(L-lactic acid) containing lauric anhydride, in amounts respectively, 2% and 5% by weight of the blend, were prepared by first dry blending the solid materials and then solution blending the materials by roller mixing the solid mixture (10% by weight) with chloroform (90% by weight). After complete dissolution of the solids, the solutions were cast onto an open tray, left to dry (in a fume cupboard) at ambient temperature for 24 hours and dried for a further 24 hours under vacuum at ambient temperature. A control sample was also prepared by solution blending poly(L-lactic acid) alone with chloroform and drying the cast solution under the same conditions as the lauric acid-containing samples.
The dried cast films were then comminuted and approximately 10gm charges of the blends were compression moulded between two sheets of mould release sheets maintained 0.5mm apart. The charges were warmed for 5 minutes prior to moulding and fed into the mould at a temperature of 195 C, pressure of 100N over a period of 90 seconds to form sheets. The resultant sheets were observed to be transparent.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples of the sheets were analysed to determine molecular weight of the polymer blend(to measure the degree of degradation). The decrease in molecular weight is reported in Figure 8.
Example 6 The process of Example 5 was repeated using a blend of poly (L-lactic acid) containing 2% by weight benzoic acid anhydride. The reduction of molecular weight with time is shown in Figure 9.
The decrease in molecular weight over the twenty week test period showed that there was very little degradation (loss in molecular weight) within the first ten weeks Example 7 The process of Example I was repeated to make blends of poly (L-lactic acid) containing 2% by weight of the following acids:
Phthalic acid 2-Hexanoic 4-Isopropylbenzoic acid Hydrocinnamic acid 2-Bromolauric acid Benzoic acid Lauric acid Undecylenic acid 2-4 Hexadienoic PLA control The results of a plot of molecular weight decreas with time is shown in Figure 10.
Example 8 The product of Example 4, ie rods of a blend of poly (L-lactic acid) containing 0.9% by weight of Lauric acid, were cut up into short lengths ( typically about 3mm). This material was then formed into an interference screw (for soft tissue anchorage) by injection moulding using an Arburg 270M All Rounder 500-90 machine with the following conditions:
Temp at nozzle = 224 C
Barrel Temp = 235 C
Injection pressure = 1500 bar Mould temp = 18 C
The resultant moulded devices had filled the mould well and were transparent.
Example 5 Blends of poly(L-lactic acid) containing lauric anhydride, in amounts respectively, 2% and 5% by weight of the blend, were prepared by first dry blending the solid materials and then solution blending the materials by roller mixing the solid mixture (10% by weight) with chloroform (90% by weight). After complete dissolution of the solids, the solutions were cast onto an open tray, left to dry (in a fume cupboard) at ambient temperature for 24 hours and dried for a further 24 hours under vacuum at ambient temperature. A control sample was also prepared by solution blending poly(L-lactic acid) alone with chloroform and drying the cast solution under the same conditions as the lauric acid-containing samples.
The dried cast films were then comminuted and approximately 10gm charges of the blends were compression moulded between two sheets of mould release sheets maintained 0.5mm apart. The charges were warmed for 5 minutes prior to moulding and fed into the mould at a temperature of 195 C, pressure of 100N over a period of 90 seconds to form sheets. The resultant sheets were observed to be transparent.
The sheets were cut into strips and subjected to simulated degradation by immersion in standard phosphate buffer solution (PBS), maintained at 37 C for 8 weeks.
During the eight week test period samples of the sheets were analysed to determine molecular weight of the polymer blend(to measure the degree of degradation). The decrease in molecular weight is reported in Figure 8.
Example 6 The process of Example 5 was repeated using a blend of poly (L-lactic acid) containing 2% by weight benzoic acid anhydride. The reduction of molecular weight with time is shown in Figure 9.
The decrease in molecular weight over the twenty week test period showed that there was very little degradation (loss in molecular weight) within the first ten weeks Example 7 The process of Example I was repeated to make blends of poly (L-lactic acid) containing 2% by weight of the following acids:
Phthalic acid 2-Hexanoic 4-Isopropylbenzoic acid Hydrocinnamic acid 2-Bromolauric acid Benzoic acid Lauric acid Undecylenic acid 2-4 Hexadienoic PLA control The results of a plot of molecular weight decreas with time is shown in Figure 10.
Example 8 The product of Example 4, ie rods of a blend of poly (L-lactic acid) containing 0.9% by weight of Lauric acid, were cut up into short lengths ( typically about 3mm). This material was then formed into an interference screw (for soft tissue anchorage) by injection moulding using an Arburg 270M All Rounder 500-90 machine with the following conditions:
Temp at nozzle = 224 C
Barrel Temp = 235 C
Injection pressure = 1500 bar Mould temp = 18 C
The resultant moulded devices had filled the mould well and were transparent.
Claims (13)
1. An implantabie, biodegradable medical device formed from a homogeneous polymer blend comprising a lactic acid polymer in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive in the form of isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen-1-yisuccinic anhydride or phthalic anhydride.
2. The implantable, biodegradable medical device of claim 1, wherein the additive is in the form of lauric anhydride or benzoic anhydride.
3. The implantable, biodegradable medical device of claim 1, wherein the polymer blend contains no more than 2% by weight of the additive.
4. The implantable, biodegradable medical device of claim 1, wherein the lactic acid polymer is poly lactic acid.
5. The implantable, biodegradable medical device of claim 1, wherein the lactic acid polymer is a copolymer with glycolic acid.
6. The implantable, biodegradable medical device of claim 1, wherein the polymer blend is a matrix component of a composite material from which the device is formed.
7. The implantable biodegradable medical device of claim 1, in a form of a suture, suture anchor, soft tissue anchor, interference screw, tissue engineering scaffold, maxial-facial plate, or a fracture fixation plate or rod.
8. A polymer blend for manufacture of biodegradable medical devices, comprising polylactic acid in admixture with an additive in an amount of not more than 10% by weight of the polymer blend, the additive being in the form of isovaleric anhydride, hexanoic anhydride, decanoic anhydride, lauric anhydride, myristic anhydride, 4-pentenoic anhydride, oleic anhydride, linoleic anhydride, benzoic anhydride, poly(azelaic anhydride), 2-octen- 1 -ylsuccinic anhydride or phthalic anhydride.
9. The polymer blend in of claim 8, comprising no more than 5% by weight of the additive.
10. The polymer blend in of claim 9, comprising no more than 2% by weight of the additive.
11. The polymer blend of claim 9, wherein the additive is in the form of lauric anhydride or benzoic anhydride.
12. A polymer blend for the manufacture of biodegradable medical devices comprising a lactic acid polymer or a lactic acid copolymer in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive in the form of lauric anhydride or benzoic anhydride.
13. An implantable, biodegradable medical device formed from a homogenous polymer blend comprising a lactic acid polymer in admixture, in an amount of not more than 10% by weight of the polymer blend, with an additive in the form of lauric anhydride or benzoic anhydride.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0116341.9A GB0116341D0 (en) | 2001-07-04 | 2001-07-04 | Biodegradable polymer systems |
GB0116341.9 | 2001-07-04 | ||
PCT/GB2002/003072 WO2003004071A1 (en) | 2001-07-04 | 2002-07-03 | Biodegradable polymer systems |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2452358A1 CA2452358A1 (en) | 2003-01-16 |
CA2452358C true CA2452358C (en) | 2010-05-04 |
Family
ID=9917916
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2452358A Expired - Fee Related CA2452358C (en) | 2001-07-04 | 2002-07-03 | Biodegradable polymer systems |
Country Status (9)
Country | Link |
---|---|
US (1) | US7524891B2 (en) |
EP (1) | EP1401510B1 (en) |
JP (1) | JP2004533308A (en) |
AT (1) | ATE527000T1 (en) |
AU (1) | AU2002310552B2 (en) |
CA (1) | CA2452358C (en) |
ES (1) | ES2374555T3 (en) |
GB (1) | GB0116341D0 (en) |
WO (1) | WO2003004071A1 (en) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0317192D0 (en) * | 2003-07-19 | 2003-08-27 | Smith & Nephew | High strength bioresorbable co-polymers |
GB0329654D0 (en) | 2003-12-23 | 2004-01-28 | Smith & Nephew | Tunable segmented polyacetal |
EP1926506A2 (en) * | 2005-08-18 | 2008-06-04 | Smith & Nephew, PLC | Multimodal high strength devices and composites |
EP1922091A2 (en) * | 2005-08-18 | 2008-05-21 | Smith & Nephew, PLC | High strength devices and composites |
WO2007103276A2 (en) | 2006-03-03 | 2007-09-13 | Smith & Nephew, Inc. | Systems and methods for delivering a medicament |
US7794495B2 (en) * | 2006-07-17 | 2010-09-14 | Advanced Cardiovascular Systems, Inc. | Controlled degradation of stents |
US8828419B2 (en) * | 2006-10-06 | 2014-09-09 | Cordis Corporation | Bioabsorbable device having encapsulated additives for accelerating degradation |
US8394488B2 (en) | 2006-10-06 | 2013-03-12 | Cordis Corporation | Bioabsorbable device having composite structure for accelerating degradation |
US20080177330A1 (en) * | 2006-10-24 | 2008-07-24 | Ralph James D | Self-locking screws for medical implants |
US20080103584A1 (en) * | 2006-10-25 | 2008-05-01 | Biosensors International Group | Temporal Intraluminal Stent, Methods of Making and Using |
US8722783B2 (en) * | 2006-11-30 | 2014-05-13 | Smith & Nephew, Inc. | Fiber reinforced composite material |
AU2008240418B2 (en) | 2007-04-18 | 2013-08-15 | Smith & Nephew Plc | Expansion moulding of shape memory polymers |
AU2008242289A1 (en) * | 2007-04-19 | 2008-10-30 | Smith & Nephew, Inc. | Shape memory polymers containing degradation accelerant |
US9770534B2 (en) | 2007-04-19 | 2017-09-26 | Smith & Nephew, Inc. | Graft fixation |
EP2142227B1 (en) | 2007-04-19 | 2012-02-29 | Smith & Nephew, Inc. | Multi-modal shape memory polymers |
GB0715376D0 (en) * | 2007-08-07 | 2007-09-19 | Smith & Nephew | Coating |
GB0813659D0 (en) * | 2008-07-25 | 2008-09-03 | Smith & Nephew | Fracture putty |
GB0819296D0 (en) * | 2008-10-21 | 2008-11-26 | Smith & Nephew | Coating II |
EP2410929B1 (en) | 2009-03-24 | 2019-06-26 | Stabiliz Orthopedics, LLC | Orthopedic fixation device with bioresorbable layer |
US9889238B2 (en) * | 2009-07-21 | 2018-02-13 | Abbott Cardiovascular Systems Inc. | Biodegradable stent with adjustable degradation rate |
US8889823B2 (en) | 2009-07-21 | 2014-11-18 | Abbott Cardiovascular Systems Inc. | Method to make poly(L-lactide) stent with tunable degradation rate |
US8506593B2 (en) | 2010-04-11 | 2013-08-13 | Lap IP, Inc | Implantable biodegradable wound closure device and method |
US20120009420A1 (en) | 2010-07-07 | 2012-01-12 | Lifoam Industries | Compostable or Biobased Foams |
US8962706B2 (en) | 2010-09-10 | 2015-02-24 | Lifoam Industries, Llc | Process for enabling secondary expansion of expandable beads |
US10525168B2 (en) | 2010-10-20 | 2020-01-07 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US10525169B2 (en) | 2010-10-20 | 2020-01-07 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11291483B2 (en) | 2010-10-20 | 2022-04-05 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
US11207109B2 (en) | 2010-10-20 | 2021-12-28 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
US11484627B2 (en) | 2010-10-20 | 2022-11-01 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
EP2629780A4 (en) | 2010-10-20 | 2014-10-01 | 206 Ortho Inc | Implantable polymer for bone and vascular lesions |
WO2014190289A2 (en) | 2013-05-23 | 2014-11-27 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
US9320601B2 (en) | 2011-10-20 | 2016-04-26 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants |
US11058796B2 (en) | 2010-10-20 | 2021-07-13 | 206 Ortho, Inc. | Method and apparatus for treating bone fractures, and/or for fortifying and/or augmenting bone, including the provision and use of composite implants, and novel composite structures which may be used for medical and non-medical applications |
CN102093540A (en) * | 2010-11-18 | 2011-06-15 | 江南大学 | Ricinoleic acid-based elastomer |
CN102030889A (en) * | 2010-11-18 | 2011-04-27 | 江南大学 | Photoresponse type polyester |
US8834776B2 (en) | 2011-05-10 | 2014-09-16 | Abbott Cardiovascular Systems Inc. | Control of degradation profile of bioabsorbable poly(l-lactide) scaffold |
US10675376B2 (en) | 2012-05-24 | 2020-06-09 | Ethicon Llc | Mechanically strong absorbable polymeric blend compositions of precisely controllable absorption rates, processing methods, and products therefrom |
US20150361326A1 (en) * | 2013-01-18 | 2015-12-17 | Kureha Corporation | Well treatment fluid material and well treatment fluid comprising the same |
RU2694057C1 (en) | 2013-11-27 | 2019-07-09 | ЭТИКОН, ЭлЭлСи | Compositions comprising mixture of absorbable polymers with accurately controlled absorption rates, processing methods, and dimensionally stable medical devices therefrom |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3531561A (en) * | 1965-04-20 | 1970-09-29 | Ethicon Inc | Suture preparation |
BE758156R (en) * | 1970-05-13 | 1971-04-28 | Ethicon Inc | ABSORBABLE SUTURE ELEMENT AND ITS |
US3797499A (en) * | 1970-05-13 | 1974-03-19 | Ethicon Inc | Polylactide fabric graphs for surgical implantation |
US3736646A (en) * | 1971-10-18 | 1973-06-05 | American Cyanamid Co | Method of attaching surgical needles to multifilament polyglycolic acid absorbable sutures |
US4137921A (en) * | 1977-06-24 | 1979-02-06 | Ethicon, Inc. | Addition copolymers of lactide and glycolide and method of preparation |
US4181983A (en) * | 1977-08-29 | 1980-01-08 | Kulkarni R K | Assimilable hydrophilic prosthesis |
US5110852A (en) * | 1982-07-16 | 1992-05-05 | Rijksuniversiteit Te Groningen | Filament material polylactide mixtures |
US4700704A (en) | 1982-10-01 | 1987-10-20 | Ethicon, Inc. | Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same |
US4523591A (en) * | 1982-10-22 | 1985-06-18 | Kaplan Donald S | Polymers for injection molding of absorbable surgical devices |
US4539981A (en) * | 1982-11-08 | 1985-09-10 | Johnson & Johnson Products, Inc. | Absorbable bone fixation device |
US4438253A (en) * | 1982-11-12 | 1984-03-20 | American Cyanamid Company | Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same |
US4643734A (en) * | 1983-05-05 | 1987-02-17 | Hexcel Corporation | Lactide/caprolactone polymer, method of making the same, composites thereof, and prostheses produced therefrom |
US4636215A (en) * | 1984-01-11 | 1987-01-13 | Rei, Inc. | Combination tray and condylar prosthesis for mandibular reconstruction and the like |
US4840632A (en) * | 1984-03-16 | 1989-06-20 | Kampner Stanley L | Hip prosthesis |
US4990161A (en) * | 1984-03-16 | 1991-02-05 | Kampner Stanley L | Implant with resorbable stem |
US4559945A (en) | 1984-09-21 | 1985-12-24 | Ethicon, Inc. | Absorbable crystalline alkylene malonate copolyesters and surgical devices therefrom |
US4776329A (en) | 1985-09-20 | 1988-10-11 | Richards Medical Company | Resorbable compressing screw and method |
US6005161A (en) | 1986-01-28 | 1999-12-21 | Thm Biomedical, Inc. | Method and device for reconstruction of articular cartilage |
FI81498C (en) | 1987-01-13 | 1990-11-12 | Biocon Oy | SURGICAL MATERIAL OCH INSTRUMENT. |
US5527337A (en) * | 1987-06-25 | 1996-06-18 | Duke University | Bioabsorbable stent and method of making the same |
JP2561853B2 (en) * | 1988-01-28 | 1996-12-11 | 株式会社ジェイ・エム・エス | Shaped memory molded article and method of using the same |
US4858603A (en) * | 1988-06-06 | 1989-08-22 | Johnson & Johnson Orthopaedics, Inc. | Bone pin |
US5444113A (en) * | 1988-08-08 | 1995-08-22 | Ecopol, Llc | End use applications of biodegradable polymers |
US5502158A (en) | 1988-08-08 | 1996-03-26 | Ecopol, Llc | Degradable polymer composition |
JPH0739506B2 (en) * | 1988-09-30 | 1995-05-01 | 三菱重工業株式会社 | Shape memory polymer foam |
US4938763B1 (en) * | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
US5633002A (en) * | 1988-10-04 | 1997-05-27 | Boehringer Ingelheim Gmbh | Implantable, biodegradable system for releasing active substance |
FI85223C (en) * | 1988-11-10 | 1992-03-25 | Biocon Oy | BIODEGRADERANDE SURGICAL IMPLANT OCH MEDEL. |
FR2641692A1 (en) * | 1989-01-17 | 1990-07-20 | Nippon Zeon Co | Plug for closing an opening for a medical application, and device for the closure plug making use thereof |
US5522817A (en) * | 1989-03-31 | 1996-06-04 | United States Surgical Corporation | Absorbable surgical fastener with bone penetrating elements |
US5108755A (en) * | 1989-04-27 | 1992-04-28 | Sri International | Biodegradable composites for internal medical use |
US5294395A (en) * | 1989-09-01 | 1994-03-15 | Ethicon, Inc. | Thermal treatment of theraplastic filaments for the preparation of surgical sutures |
US5201771A (en) * | 1989-09-15 | 1993-04-13 | Belykh Sergei I | Endoprosthesis of the hip joint |
US7208013B1 (en) * | 1990-06-28 | 2007-04-24 | Bonutti Ip, Llc | Composite surgical devices |
IL94910A (en) | 1990-06-29 | 1994-04-12 | Technion Research Dev Foundati | Biomedical adhesive compositions |
US5201738A (en) * | 1990-12-10 | 1993-04-13 | Johnson & Johnson Orthopaedics, Inc. | Biodegradable biocompatible anti-displacement device for prosthetic bone joints |
CA2062012C (en) | 1991-03-05 | 2003-04-29 | Randall D. Ross | Bioabsorbable interference bone fixation screw |
ATE131373T1 (en) * | 1991-05-24 | 1995-12-15 | Synthes Ag | ABSORBABLE TENDON AND BONE REINFORCEMENT DEVICE |
EP0523926A3 (en) | 1991-07-15 | 1993-12-01 | Smith & Nephew Richards Inc | Prosthetic implants with bioabsorbable coating |
US5275601A (en) * | 1991-09-03 | 1994-01-04 | Synthes (U.S.A) | Self-locking resorbable screws and plates for internal fixation of bone fractures and tendon-to-bone attachment |
US5500013A (en) | 1991-10-04 | 1996-03-19 | Scimed Life Systems, Inc. | Biodegradable drug delivery vascular stent |
US5360448A (en) | 1991-10-07 | 1994-11-01 | Thramann Jeffrey J | Porous-coated bone screw for securing prosthesis |
US5383931A (en) * | 1992-01-03 | 1995-01-24 | Synthes (U.S.A.) | Resorbable implantable device for the reconstruction of the orbit of the human skull |
FI95537C (en) | 1992-01-24 | 1996-02-26 | Biocon Oy | Surgical implant |
AU672596B2 (en) | 1992-02-14 | 1996-10-10 | Smith & Nephew, Inc. | Polymeric screws and coatings for surgical uses |
US5333624A (en) * | 1992-02-24 | 1994-08-02 | United States Surgical Corporation | Surgical attaching apparatus |
US5571193A (en) | 1992-03-12 | 1996-11-05 | Kampner; Stanley L. | Implant with reinforced resorbable stem |
WO1993022987A2 (en) * | 1992-05-20 | 1993-11-25 | Cytrx Corporation | Gel composition for implant and method |
JP3447289B2 (en) * | 1992-10-02 | 2003-09-16 | カーギル, インコーポレイテッド | Melt-stable lactide polymer fiber and method for producing the same |
US5376120A (en) | 1992-10-21 | 1994-12-27 | Biomet, Inc. | Biocompatible implant and method of using same |
US5437918A (en) * | 1992-11-11 | 1995-08-01 | Mitsui Toatsu Chemicals, Inc. | Degradable non-woven fabric and preparation process thereof |
FR2701214B1 (en) | 1993-02-08 | 1998-07-31 | Nippon Zeon Co | Catheter and method of making the same. |
US5441515A (en) * | 1993-04-23 | 1995-08-15 | Advanced Cardiovascular Systems, Inc. | Ratcheting stent |
US5716410A (en) * | 1993-04-30 | 1998-02-10 | Scimed Life Systems, Inc. | Temporary stent and method of use |
US6315788B1 (en) | 1994-02-10 | 2001-11-13 | United States Surgical Corporation | Composite materials and surgical articles made therefrom |
US5417712A (en) * | 1994-02-17 | 1995-05-23 | Mitek Surgical Products, Inc. | Bone anchor |
US5626861A (en) * | 1994-04-01 | 1997-05-06 | Massachusetts Institute Of Technology | Polymeric-hydroxyapatite bone composite |
US6001101A (en) | 1994-07-05 | 1999-12-14 | Depuy France | Screw device with threaded head for permitting the coaptation of two bone fragments |
DE4424883A1 (en) | 1994-07-14 | 1996-01-18 | Merck Patent Gmbh | Femoral prosthesis |
US5837276A (en) | 1994-09-02 | 1998-11-17 | Delab | Apparatus for the delivery of elongate solid drug compositions |
US5690671A (en) | 1994-12-13 | 1997-11-25 | Micro Interventional Systems, Inc. | Embolic elements and methods and apparatus for their delivery |
US5634936A (en) * | 1995-02-06 | 1997-06-03 | Scimed Life Systems, Inc. | Device for closing a septal defect |
DE59608020D1 (en) * | 1995-08-16 | 2001-11-29 | Frank Lampe | ENDOPROTHESIS, ESPECIALLY HIP JOINT PROSTHESIS |
FI98136C (en) * | 1995-09-27 | 1997-04-25 | Biocon Oy | A tissue-soluble material and process for its manufacture |
US6113624A (en) | 1995-10-02 | 2000-09-05 | Ethicon, Inc. | Absorbable elastomeric polymer |
US5716413A (en) * | 1995-10-11 | 1998-02-10 | Osteobiologics, Inc. | Moldable, hand-shapable biodegradable implant material |
JP3731838B2 (en) | 1996-04-30 | 2006-01-05 | 株式会社クレハ | Polyglycolic acid oriented film and method for producing the same |
US6143948A (en) | 1996-05-10 | 2000-11-07 | Isotis B.V. | Device for incorporation and release of biologically active agents |
US5670161A (en) | 1996-05-28 | 1997-09-23 | Healy; Kevin E. | Biodegradable stent |
EP0906128A1 (en) * | 1996-05-28 | 1999-04-07 | 1218122 Ontario Inc. | Resorbable implant biomaterial made of condensed calcium phosphate particles |
US5935172A (en) * | 1996-06-28 | 1999-08-10 | Johnson & Johnson Professional, Inc. | Prosthesis with variable fit and strain distribution |
US5756651A (en) * | 1996-07-17 | 1998-05-26 | Chronopol, Inc. | Impact modified polylactide |
JP4425993B2 (en) * | 1996-08-23 | 2010-03-03 | オステオバイオロジックス, インコーポレイテッド | Gripping material tester |
US5893850A (en) * | 1996-11-12 | 1999-04-13 | Cachia; Victor V. | Bone fixation device |
ES2238736T3 (en) * | 1996-12-03 | 2005-09-01 | Osteobiologics, Inc. | BIODEGRADABLE POLYMER FILM. |
US5733330A (en) * | 1997-01-13 | 1998-03-31 | Advanced Cardiovascular Systems, Inc. | Balloon-expandable, crush-resistant locking stent |
SE512050C2 (en) * | 1997-01-21 | 2000-01-17 | Nobel Biocare Ab | Rotationally symmetrical leg anchoring element |
US5997580A (en) | 1997-03-27 | 1999-12-07 | Johnson & Johnson Professional, Inc. | Cement restrictor including shape memory material |
US5810821A (en) * | 1997-03-28 | 1998-09-22 | Biomet Inc. | Bone fixation screw system |
US5977204A (en) * | 1997-04-11 | 1999-11-02 | Osteobiologics, Inc. | Biodegradable implant material comprising bioactive ceramic |
ATE412383T1 (en) * | 1997-05-30 | 2008-11-15 | Osteobiologics Inc | FIBER REINFORCED POROUS BIODEGRADABLE IMPLANT DEVICE |
US5980564A (en) | 1997-08-01 | 1999-11-09 | Schneider (Usa) Inc. | Bioabsorbable implantable endoprosthesis with reservoir |
US6001100A (en) | 1997-08-19 | 1999-12-14 | Bionx Implants Oy | Bone block fixation implant |
US6013080A (en) * | 1997-10-30 | 2000-01-11 | Johnson & Johnson Professional, Inc. | Tamp with horizontal steps used for impaction bone grafting in revision femur |
SE510868C2 (en) * | 1997-11-03 | 1999-07-05 | Artimplant Dev Artdev Ab | Molds for use as implants in human medicine and a method for making such molds |
US6150497A (en) | 1998-01-14 | 2000-11-21 | Sherwood Services Ag | Method for the production of polyglycolic acid |
HU222543B1 (en) | 1998-02-23 | 2003-08-28 | Massachusetts Institute Of Technology | Biodegradable shape memory polymers |
US20020022588A1 (en) * | 1998-06-23 | 2002-02-21 | James Wilkie | Methods and compositions for sealing tissue leaks |
JP2000117920A (en) * | 1998-08-11 | 2000-04-25 | Dainippon Ink & Chem Inc | Lactic acid type polymer laminate and molded article |
US6248430B1 (en) * | 1998-08-11 | 2001-06-19 | Dainippon Ink And Chemicals, Inc. | Lactic acid-based polymer laminated product and molded product |
SE515572C2 (en) * | 1998-09-09 | 2001-09-03 | Lanka Ltd | Implants, ways of making it and using it |
JP2000085054A (en) * | 1998-09-14 | 2000-03-28 | Daicel Chem Ind Ltd | Collapsible laminate and manufacture thereof |
US6248108B1 (en) * | 1998-09-30 | 2001-06-19 | Bionx Implants Oy | Bioabsorbable surgical screw and washer system |
US6162225A (en) | 1998-10-26 | 2000-12-19 | Musculoskeletal Transplant Foundation | Allograft bone fixation screw method and apparatus |
DE69822470T2 (en) * | 1998-11-12 | 2005-01-20 | Takiron Co. Ltd. | Biodegradable absorbable shape memory material |
US6283973B1 (en) | 1998-12-30 | 2001-09-04 | Depuy Orthopaedics, Inc. | Strength fixation device |
US6147135A (en) | 1998-12-31 | 2000-11-14 | Ethicon, Inc. | Fabrication of biocompatible polymeric composites |
US6293950B1 (en) | 1999-01-15 | 2001-09-25 | Luitpold Pharmaceuticals, Inc. | Resorbable pin systems |
EP1148830A1 (en) * | 1999-02-04 | 2001-10-31 | Synthes Ag Chur | Bone screw |
US6206883B1 (en) * | 1999-03-05 | 2001-03-27 | Stryker Technologies Corporation | Bioabsorbable materials and medical devices made therefrom |
US6187008B1 (en) * | 1999-07-07 | 2001-02-13 | Bristol-Myers Squibb | Device for temporarily fixing bones |
US7033603B2 (en) * | 1999-08-06 | 2006-04-25 | Board Of Regents The University Of Texas | Drug releasing biodegradable fiber for delivery of therapeutics |
DE59901090D1 (en) * | 1999-12-23 | 2002-05-02 | Storz Karl Gmbh & Co Kg | Decentralized drive screw |
US6423062B2 (en) * | 2000-02-18 | 2002-07-23 | Albert Enayati | Bioabsorbable pin for external bone fixation |
US6425923B1 (en) * | 2000-03-07 | 2002-07-30 | Zimmer, Inc. | Contourable polymer filled implant |
US6468277B1 (en) | 2000-04-04 | 2002-10-22 | Ethicon, Inc. | Orthopedic screw and method |
AU2001245346A1 (en) * | 2000-06-28 | 2002-01-08 | Atul J. Shukla | Biodegradable vehicles and delivery systems of biologically active substances |
EP1309279A4 (en) * | 2000-08-17 | 2008-04-09 | Tyco Healthcare | Sutures and coatings made from therapeutic absorbable glass |
US6605090B1 (en) * | 2000-10-25 | 2003-08-12 | Sdgi Holdings, Inc. | Non-metallic implant devices and intra-operative methods for assembly and fixation |
US6719935B2 (en) * | 2001-01-05 | 2004-04-13 | Howmedica Osteonics Corp. | Process for forming bioabsorbable implants |
US6471707B1 (en) | 2001-05-11 | 2002-10-29 | Biomet | Bone screw having bioresorbable proximal shaft portion |
US6749639B2 (en) * | 2001-08-27 | 2004-06-15 | Mayo Foundation For Medical Education And Research | Coated prosthetic implant |
US6841111B2 (en) * | 2001-08-31 | 2005-01-11 | Basf Corporation | Method for making a polyurea-polyurethane composite structure substantially free of volatile organic compounds |
US6916321B2 (en) * | 2001-09-28 | 2005-07-12 | Ethicon, Inc. | Self-tapping resorbable two-piece bone screw |
US20030125745A1 (en) * | 2001-11-05 | 2003-07-03 | Bio One Tech Inc. | Bone-fixing device |
EP1460977B1 (en) * | 2001-12-21 | 2006-08-30 | Smith & Nephew, Inc. | Hinged joint system |
GB0202233D0 (en) * | 2002-01-31 | 2002-03-20 | Smith & Nephew | Bioresorbable polymers |
WO2003080119A1 (en) * | 2002-03-26 | 2003-10-02 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Responsive biomedical composites |
US7261734B2 (en) * | 2002-04-23 | 2007-08-28 | Boston Scientific Scimed, Inc. | Resorption-controllable medical implants |
US20040024471A1 (en) * | 2002-06-27 | 2004-02-05 | Ferree Bret A. | Bone cell covered arthroplasty devices |
KR20050088380A (en) * | 2002-12-12 | 2005-09-05 | 오스테오테크, 인코포레이티드 | Formable and settable polymer bone composite and method of production thereof |
EP1433489A1 (en) * | 2002-12-23 | 2004-06-30 | Degradable Solutions AG | Biodegradable porous bone implant with a barrier membrane sealed thereto |
WO2004065450A2 (en) * | 2003-01-16 | 2004-08-05 | Carnegie Mellon University | Biodegradable polyurethanes and use thereof |
US20040156878A1 (en) * | 2003-02-11 | 2004-08-12 | Alireza Rezania | Implantable medical device seeded with mammalian cells and methods of treatment |
US20070043376A1 (en) * | 2003-02-21 | 2007-02-22 | Osteobiologics, Inc. | Bone and cartilage implant delivery device |
JP4251061B2 (en) * | 2003-10-03 | 2009-04-08 | ブリヂストンスポーツ株式会社 | Golf club head |
EP1711128A4 (en) * | 2004-01-16 | 2008-07-30 | Osteobiologics Inc | Bone-tendon-bone implant |
WO2005077039A2 (en) * | 2004-02-05 | 2005-08-25 | Osteobiologics, Inc. | Absorbable orthopedic implants |
US20060067971A1 (en) * | 2004-09-27 | 2006-03-30 | Story Brooks J | Bone void filler |
EP1835867A2 (en) * | 2004-11-30 | 2007-09-26 | Osteobiologics, Inc. | Implants and delivery system for treating defects in articulating surfaces |
US7772352B2 (en) * | 2005-01-28 | 2010-08-10 | Bezwada Biomedical Llc | Bioabsorbable and biocompatible polyurethanes and polyamides for medical devices |
AU2006210847A1 (en) * | 2005-02-01 | 2006-08-10 | Osteobiologics, Inc. | Method and device for selective addition of a bioactive agent to a multi-phase implant |
WO2007067625A2 (en) * | 2005-12-06 | 2007-06-14 | Tyco Healthcare Group Lp | Bioabsorbable surgical composition |
CN101336315B (en) * | 2005-12-07 | 2012-12-19 | 特拉维夫大学拉莫特有限公司 | Drug-delivering composite structures |
WO2007084725A2 (en) * | 2006-01-19 | 2007-07-26 | Osteotech, Inc. | Injectable and moldable bone substitute materials |
-
2001
- 2001-07-04 GB GBGB0116341.9A patent/GB0116341D0/en not_active Ceased
-
2002
- 2002-07-03 CA CA2452358A patent/CA2452358C/en not_active Expired - Fee Related
- 2002-07-03 WO PCT/GB2002/003072 patent/WO2003004071A1/en active Application Filing
- 2002-07-03 EP EP02735663A patent/EP1401510B1/en not_active Expired - Lifetime
- 2002-07-03 AT AT02735663T patent/ATE527000T1/en not_active IP Right Cessation
- 2002-07-03 AU AU2002310552A patent/AU2002310552B2/en not_active Ceased
- 2002-07-03 US US10/482,371 patent/US7524891B2/en not_active Expired - Fee Related
- 2002-07-03 JP JP2003510080A patent/JP2004533308A/en active Pending
- 2002-07-03 ES ES02735663T patent/ES2374555T3/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
ES2374555T3 (en) | 2012-02-17 |
ATE527000T1 (en) | 2011-10-15 |
CA2452358A1 (en) | 2003-01-16 |
US7524891B2 (en) | 2009-04-28 |
GB0116341D0 (en) | 2001-08-29 |
WO2003004071A1 (en) | 2003-01-16 |
EP1401510B1 (en) | 2011-10-05 |
EP1401510A1 (en) | 2004-03-31 |
AU2002310552B2 (en) | 2007-12-13 |
US20040242722A1 (en) | 2004-12-02 |
JP2004533308A (en) | 2004-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2452358C (en) | Biodegradable polymer systems | |
AU2002310552A1 (en) | Biodegradable polymer systems | |
RU2435797C2 (en) | Resorbable block copolymers of polyethers and polyesters and use thereof in producing medical implants | |
Farrar et al. | Hydrolytic degradation of polyglyconate B: the relationship between degradation time, strength and molecular weight | |
Vert et al. | More about the degradation of LA/GA-derived matrices in aqueous media | |
Cameron et al. | Synthetic bioresorbable polymers | |
DE60035403T2 (en) | BIOLOGICAL MATERIALS | |
EP0376656B1 (en) | Absorbable coating and blend | |
JP4515762B2 (en) | Poly (L-lactide-co-glycolide) copolymer and medical device containing said compound | |
Schwach et al. | In vitro and in vivo degradation of lactic acid-based interference screws used in cruciate ligament reconstruction | |
US7186759B2 (en) | Biologically active material | |
US20080305144A1 (en) | High Strength Devices and Composites | |
RU2694057C1 (en) | Compositions comprising mixture of absorbable polymers with accurately controlled absorption rates, processing methods, and dimensionally stable medical devices therefrom | |
US20090274742A1 (en) | Multimodal high strength devices and composites | |
EP2852417B1 (en) | Resorbable bioceramic compositions of poly-4-hydroxybutyrate and copolymers | |
Niemelä | Effect of β-tricalcium phosphate addition on the in vitro degradation of self-reinforced poly-l, d-lactide | |
Wach et al. | Carboxymethylchitosan hydrogel manufactured by radiation-induced crosslinking as potential nerve regeneration guide scaffold | |
Adamus et al. | Degradation of nerve guidance channels based on a poly (L-lactic acid) poly (trimethylene carbonate) biomaterial | |
Li | Synthetic biodegradable medical polyesters | |
Liu et al. | Synthesis, Properties, and In Vitro Hydrolytic Degradation of Poly (d, l-lactide-co-glycolide-co-ε-caprolactone) | |
CN109970956B (en) | Degradable polyester composite material prepared based on carboxylic acid related to Krebs cycle and preparation method and application thereof | |
Mobedi et al. | L-lactide additive and in vitro degradation performance of poly (l-lactide) films | |
Kyhkynen | Controlled drug delivery from porous lactide-based polymers | |
Vogt et al. | Novel Polylactide‐Based Release Systems for Local Antibiotic Therapies | |
Vert | Understanding of the Bioresorption of PLA/GA Polymers with Respect |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140703 |